BOSTON--Researchers at New England Deaconess Hospital are seeking
patients with Hodgkin's disease, non-Hodgkin's lymphoma, acute
myelogenous leukemia (AML), and chronic myelogenous leukemia (CML)
for an FDA-sponsored study of a humanized anti-Tac (interleukin-2
receptor) monoclonal antibody. The phase Ib/II multidose trial
will study tolerance, therapeutic efficacy, and biological efficacy.
The protocol (92-0205-34) calls for patients over the age of 18
with a life expectancy greater than 2 months and confirmed Tac
on malignant cells, except for Hodgkin's disease patients, for
which all R-S (Reed-Sternberg) cells are Tac-positive. Also, patients
must be able to have continuous local access for 1 month.
Hodgkin's disease patients (25 to be enrolled) must have failed
first-line therapy and one salvage attempt. Non-Hodgkin's lymphoma
patients with aggressive disease must have failed first-line therapy;
if indolent, any patient is eligible. All CML patients (eight
to be enrolled) are eligible. AML patients (eight to be enrolled)
must have failed first-line therapy or be in first or later relapse.
For more information, contact Dan Hagg, New England Deaconess
Hospital, 21-27 Burlington Avenue, 5th Floor, Boston, MA 02215.